Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Dollar Steady as Markets Await U.S. Inflation Data 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Gold Prices Rise as Fed Rate Hike Bets Ease 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
GSK and Medicago are now closer to debuting the world's first plant-based COVID-19 vaccine after the completion of phase 3 clinical trial for the efficacy and safety of the immunization that they are developing.
This week, GlaxoSmithKline and Medicago announced getting positive results for their plant-based vaccine candidate for coronavirus. The product is Canadian-made, and it was found to be 71% effective after going through the third level of tests.
According to Canada's CTV News, Medicago Inc., the biotech company headquartered in Quebec, said their Phase 3 placebo-controlled study for their COVID-19 vaccine was conducted in over 24,000 subjects based in six countries.
The participants were 18 years old and older, and the outcome revealed the 71% effectiveness against all variants of coronavirus that were active at the time of the trial. The company further said that they did not find any serious safety issues as well.
The positive results were forwarded to regulators already so it can be authorized to release the world's very first plant-based COVID-19 vaccine worldwide. Just like the other available vaccines today, Medicago and GSK's candidate is also a two-dose injection.
Then again, while the biotech firm said its new vaccine was tested to be effective against the Delta variant but the trial did not include the Omicron variant because it was not yet circulating when the study began.
Currently, the vaccine producer is now processing documents and requirements for filing with health regulators in the U.K., U.S., and other nations. They will also forward the necessary data to World Health Organisation (WHO).
"This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology," Medicago chief executive officer and president Takashi Nagao said in a press release. "If approved, we will be contributing to the world's fight against the COVID-19 pandemic with the world's first plant-based vaccine for use in humans."
Finally, Nagao also expressed his gratitude to everyone who took part in the clinical trials, including its partners at GSK, Mitsubishi Tanabe Pharma Corporation, and the government of Canada and Quebec. He did not forget to thank Medicago's workers and shareholders, who are also committed to work on advancing vaccine science at a time when the world needs it.
